Introduction: Achievement of an initial complete remission (CR) following induction chemotherapy is tightly correlated with survival in acute myeloid leukemia (AML) patients, yet patients in CR with incomplete hematologic recovery (CRi) still experience improved outcomes compared with nonresponding patients. Whether CRi predicts prognosis in patients referred to an allogeneic stem cell transplantation (allo-SCT) is incompletely defined. In this analysis, we evaluated whether clinical outcomes of transplanted AML patients in CR and CRi were significantly different. Methods: A retrospective single-center analysis of all de novo AML patients who underwent an allo-SCT between 2001 and 2015. The cohort included all adult patients with AML who underwent a first allo-SCT either in first or second CR or CRi at the time of transplantation. Results: The study cohort included 186 CR patients and 44 CRi patients. In univariate analysis, CRi was associated with inferior 3-year survival and 3-year nonrelapse mortality (NRM) compared to CR (41 vs. 62%; p = 0.022 and 27 vs. 10%; p = 0.006, respectively). In multivariate analysis, CRi was associated with decreased rates of survival (hazard ratio [HR] 2.01; 95% CI, 1.24–3.25; p = 0.005) and NRM (HR, 3.5; 95% CI, 1.6–7.8; p = 0.002). Conclusion: CRi in transplanted AML patients is potentially a potent predictor of increased NRM and survival.

1.
Cheson
BD
,
Bennett
JM
,
Kopecky
KJ
,
Büchner
T
,
Willman
CL
,
Estey
EH
,
Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
.
J Clin Oncol
.
2003
;
21
(
24
):
4642
9
. .
2.
Bloomfield
CD
,
Estey
E
,
Pleyer
L
,
Schuh
AC
,
Stein
EM
,
Tallman
MS
,
Time to repeal and replace response criteria for acute myeloid leukemia?
Blood Rev
.
2018
;
32
(
5
):
416
25
. .
3.
Perl
AE
.
Availability of FLT3 inhibitors: how do we use them?
Blood
.
2019
;
134
(
9
):
741
5
. .
4.
Walter
RB
,
Kantarjian
HM
,
Huang
X
,
Pierce
SA
,
Sun
Z
,
Gundacker
HM
,
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
.
J Clin Oncol
.
2010
;
28
(
10
):
1766
71
. .
5.
Chen
X
,
Xie
H
,
Wood
BL
,
Walter
RB
,
Pagel
JM
,
Becker
PS
,
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia
.
J Clin Oncol
.
2015
;
33
(
11
):
1258
64
. .
6.
Dohner
H
,
Estey
E
,
Grimwade
D
,
Amadori
S
,
Appelbaum
FR
,
Buchner
T
,
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
;
129
(
4
):
424
47
.
7.
Grimwade
D
,
Walker
H
,
Oliver
F
,
Wheatley
K
,
Harrison
C
,
Harrison
G
,
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties
.
Blood
.
1998
;
92
(
7
):
2322
33
.
8.
Aoudjhane
M
,
Labopin
M
,
Gorin
NC
,
Shimoni
A
,
Ruutu
T
,
Kolb
HJ
,
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
.
Leukemia
.
2005
;
19
(
12
):
2304
12
. .
9.
Ovlisen
AK
,
Oest
A
,
Bendtsen
MD
,
Baech
J
,
Johansen
P
,
Lynggaard
LS
,
Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study
.
Blood Adv
.
2018
;
2
(
5
):
559
64
.
10.
Alatrash
G
,
Pelosini
M
,
Saliba
RM
,
Koca
E
,
Rondon
G
,
Andersson
BS
,
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
.
Biol Blood Marrow Transplant
.
2011
;
17
(
12
):
1841
5
. .
11.
Cheng
W-Y
,
Zhu
Y-M
,
Liu
Z
,
Weng
X-Q
,
Sui
J-N
,
Chen
Y-S
,
Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state
.
Blood Cancer J
.
2018
;
8
(
6
):
53
. .
12.
Innes
AJ
,
Woolley
9
,
Szydlo
RM
,
Lozano
S
,
Fernando
F
,
Bansal
D
,
Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality
.
Leukemia
.
2020 Feb
;
34
(
2
):
667
70
.
13.
Vu
K
,
Manjappa
S
,
DiPersio
JF
,
Gao
F
,
Westervelt
P
,
Vij
R
,
Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
.
Biol Blood Marrow Transplant
.
2015
;
21
(
8
):
1425
30
. .
14.
Canaani
J
,
Beohou
E
,
Labopin
M
,
Ghavamzadeh
A
,
Beelen
D
,
Hamladji
RM
,
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
.
J Intern Med
.
2019
;
285
(
4
):
407
18
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.